These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36604833)

  • 1. Ratio and difference of average hazard with survival weight: New measures to quantify survival benefit of new therapy.
    Uno H; Horiguchi M
    Stat Med; 2023 Mar; 42(7):936-952. PubMed ID: 36604833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression models for average hazard.
    Uno H; Tian L; Horiguchi M; Hattori S; Kehl KL
    Biometrics; 2024 Mar; 80(2):. PubMed ID: 38771658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.
    Pak K; Uno H; Kim DH; Tian L; Kane RC; Takeuchi M; Fu H; Claggett B; Wei LJ
    JAMA Oncol; 2017 Dec; 3(12):1692-1696. PubMed ID: 28975263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of Restricted Mean Survival Time Based Methods and Traditional Survival Methods: An Application in an Oncological Data.
    Huang Q; Tian C
    Comput Math Methods Med; 2022; 2022():7264382. PubMed ID: 36619796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On assessing survival benefit of immunotherapy using long-term restricted mean survival time.
    Horiguchi M; Tian L; Uno H
    Stat Med; 2023 Apr; 42(8):1139-1155. PubMed ID: 36653933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies.
    Pang H; Yang G; Ho JC; Leung TH; Shi Q; Hu C; Stinchcombe TE; Wang X
    Chin Clin Oncol; 2022 Feb; 11(1):7. PubMed ID: 35255696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic RMST curves for survival analysis in clinical trials.
    Liao JJZ; Liu GF; Wu WC
    BMC Med Res Methodol; 2020 Aug; 20(1):218. PubMed ID: 32854619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer.
    Liang F; Zhang S; Wang Q; Li W
    Ann Oncol; 2018 May; 29(5):1320-1324. PubMed ID: 29788167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of different population-level summary measures for randomised trials with time-to-event outcomes, with a focus on non-inferiority trials.
    Quartagno M; Morris TP; Gilbert DC; Langley RE; Nankivell MG; Parmar MK; White IR
    Clin Trials; 2023 Dec; 20(6):594-602. PubMed ID: 37337728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restricted mean survival time as a summary measure of time-to-event outcome.
    Hasegawa T; Misawa S; Nakagawa S; Tanaka S; Tanase T; Ugai H; Wakana A; Yodo Y; Tsuchiya S; Suganami H;
    Pharm Stat; 2020 Jul; 19(4):436-453. PubMed ID: 32072769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity Analysis for Restricted Mean Survival Time When Survival Curves Have Divergent Tails.
    Ueno K; Morita S
    Ther Innov Regul Sci; 2023 May; 57(3):467-471. PubMed ID: 36596962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Application of restricted mean survival time in clinical follow-up study].
    Yang ZJ; Lyu JJ; Hou YW; Chen Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Feb; 40(2):247-250. PubMed ID: 30744281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.
    Zhao L; Tian L; Uno H; Solomon SD; Pfeffer MA; Schindler JS; Wei LJ
    Clin Trials; 2012 Oct; 9(5):570-7. PubMed ID: 22914867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated?
    Horiguchi M; Hassett MJ; Uno H
    Oncologist; 2019 Jul; 24(7):867-871. PubMed ID: 30201741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
    Huang B; Kuan PF
    Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.
    Trinquart L; Jacot J; Conner SC; Porcher R
    J Clin Oncol; 2016 May; 34(15):1813-9. PubMed ID: 26884584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing surrogacy using restricted mean survival time ratio for overall survival in liver cancer: a narrative review.
    Leung TH; Ho JC; Wang X; Pang H
    Chin Clin Oncol; 2023 Oct; 12(5):53. PubMed ID: 37817506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantifying treatment differences in confirmatory trials under non-proportional hazards.
    Jiménez JL
    J Appl Stat; 2022; 49(2):466-484. PubMed ID: 35707213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interpretation and Application of Restricted Mean Survival Time].
    Hasegawa T
    Gan To Kagaku Ryoho; 2022 Apr; 49(4):389-396. PubMed ID: 35444119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.